scholarly journals A MicroRNA Panel in Pancreatic Cyst Fluid for the Risk Stratification of Pancreatic Cysts in a Prospective Cohort

2016 ◽  
Vol 5 ◽  
pp. e350 ◽  
Author(s):  
WK Utomo ◽  
LH Looijenga ◽  
MJ Bruno ◽  
BE Hansen ◽  
AJM Gillis ◽  
...  
Keyword(s):  
Risk Stratification ◽  
Prospective Cohort ◽  
Pancreatic Cyst ◽  
Cyst Fluid ◽  
Pancreatic Cysts ◽  
Pancreatic Cyst Fluid

Su1485 Validation of a 9-microRNA Panel in Pancreatic Cyst Fluid for the Risk Stratification of Pancreatic Cysts in a Prospective Cohort

2015 ◽  
Vol 148 (4) ◽  
pp. S-526
Author(s):  
Wesley K. Utomo ◽  
Leendert Looijenga ◽  
Marco J. Bruno ◽  
Maikel P. Peppelenbosch ◽  
Henri Braat
Keyword(s):  
Risk Stratification ◽  
Prospective Cohort ◽  
Pancreatic Cyst ◽  
Cyst Fluid ◽  
Pancreatic Cysts ◽  
Pancreatic Cyst Fluid

Pancreatic cyst fluid DNA analysis in evaluating pancreatic cysts: a report of the PANDA study

2009 ◽  
Vol 69 (6) ◽  
pp. 1095-1102 ◽  
Author(s):  
Asif Khalid ◽  
Maliha Zahid ◽  
Sydney D. Finkelstein ◽  
Julia K. LeBlanc ◽  
Neeraj Kaushik ◽  
...  
Keyword(s):  
Dna Analysis ◽  
Pancreatic Cyst ◽  
Cyst Fluid ◽  
Pancreatic Cysts ◽  
Pancreatic Cyst Fluid

Exosomal miRNA signature of pancreatic cyst: Liquid biopsies as indicators of pancreatic cancer.

2018 ◽  
Vol 36 (4_suppl) ◽  
pp. 225-225
Author(s):  
Virendra Joshi ◽  
Dominic Guanzon ◽  
Cris Molina ◽  
Zarin Nuzhat ◽  
Gregory Rice ◽  
...  
Keyword(s):  
Pancreatic Cancer ◽  
Small Rna ◽  
Pancreatic Cyst ◽  
Cyst Fluid ◽  
Pancreatic Cysts ◽  
Liquid Biopsies ◽  
Pancreatic Fluid ◽  
Mucinous Neoplasms ◽  
Exosomal Mirna ◽  
Pancreatic Cyst Fluid

225 Background: Pancreatic cysts are a group of lesions with malignant potential. Currently, there are no consistently reliable biomarkers or imaging modalities to accurately predict biologic behavior of these cysts. We tested the hypothesis that tumor-derived exosomes (better conserved than free miRNA) can be acquired endoscopically from pancreatic cyst fluid and may allow for improved distinction between benign, premalignant and malignant cysts. Methods: Exosomes were isolated and characterised by differential and buoyant centrifugation from pancreatic cyst fluid obtained from 30 patients with pseudocysts (PS), serous cystic (SC), mucinous cysts (MC), intraductal papillary mucinous neoplasms (IPMN), pancreatitis (PA), and pancreatic cancer (PC) , confirmed with imaging and histology. An Illumina TruSeq Small RNA kit was used to construct a small RNA library, and the libraries were sequenced using the Illumina NextSeq 500 platform. The resulting sequencing FASTQ files were analyzed using miRDeep2 to identify both known and novel miRNAs. Results: Four significant miRNAs which are shared between six of the analyses, specifically hsa-miR-199b-3p, hsa-miR-199a-2-3p, hsa-miR-199a-1-3p and hsa-let-7i-5p were identified. MiRNA hsa-miR-27a-3p was significant and shared between five of the analyses. A total of 15, 12 and 2 significant miRNAs were shared between four, three and two of the analyses, respectively. Importantly, there were a total of 10 significant miRNAs which were unique to each analysis, with the exception of IPMN vs Pseudocyst, and Pancreatic cancer vs Pancreatitis. Specifically these unique miRNAs for each analysis are: hsa-miR-92a-2-3p (Pancreatitis vs Pseudocyst); hsa-miR-92a-1-3p (Serous vs Pseudocyst); hsa-miR-30e-5p (Pancreatic cancer vs Serous), hsa-miR-30b-5p (IPMN vs Pancreatic cancer); and hsa-miR-23b-3p, hsa-miR-99b-5p, hsa-miR-222-3p, hsa-miR-31-5p, hsa-miR-151a-5p, hsa-miR-221-3p (Pancreatic cancer vs. Pseudocyst). Conclusions: Exosomal miRNAs in pancreatic fluid may be used as a biomarker to differentiate between various cyst types and pancreatic cancer. A larger cohort with miRNA quantification and is needed to further validate these findings .

scholarly journals Pancreatic cyst fluid glucose: rapid, inexpensive, and accurate diagnosis of mucinous pancreatic cysts

Surgery ◽  
2018 ◽  
Vol 163 (3) ◽  
pp. 600-605 ◽  
Author(s):  
Rosalie A. Carr ◽  
Michele T. Yip-Schneider ◽  
Rachel E. Simpson ◽  
Scott Dolejs ◽  
Justine G. Schneider ◽  
...  
Keyword(s):  
Pancreatic Cyst ◽  
Accurate Diagnosis ◽  
Cyst Fluid ◽  
Pancreatic Cysts ◽  
Pancreatic Cyst Fluid

PANCREATIC CYST FLUID CEA AND AMYLASE IN THE DIFFERENTIAL DIAGNOSIS OF PANCREATIC CYSTS

Pancreas ◽  
2007 ◽  
Vol 35 (4) ◽  
pp. 421
Author(s):  
M. Pelaez-Luna ◽  
M. Ranjan ◽  
J. E. Clain ◽  
M. J. Levy ◽  
E. Rajan ◽  
...  
Keyword(s):  
Differential Diagnosis ◽  
Pancreatic Cyst ◽  
Cyst Fluid ◽  
Pancreatic Cysts ◽  
Pancreatic Cyst Fluid

Su1351 Amphiregulin in Pancreatic Cyst Fluid is Elevated in High-Risk Pancreatic Cysts

2016 ◽  
Vol 150 (4) ◽  
pp. S500-S501
Author(s):  
Kimberly Pham ◽  
Aiwen Dong ◽  
Dariusz Wodziak ◽  
Subhas Banerjee ◽  
Shai Friedland ◽  
...  
Keyword(s):  
High Risk ◽  
Pancreatic Cyst ◽  
Cyst Fluid ◽  
Pancreatic Cysts ◽  
Pancreatic Cyst Fluid

scholarly journals Preoperative next-generation sequencing of pancreatic cyst fluid is highly accurate in cyst classification and detection of advanced neoplasia

Gut ◽  
2017 ◽  
Vol 67 (12) ◽  
pp. 2131-2141 ◽  
Author(s):  
Aatur D Singhi ◽  
Kevin McGrath ◽  
Randall E Brand ◽  
Asif Khalid ◽  
Herbert J Zeh ◽  
...  
Keyword(s):  
Next Generation Sequencing ◽  
Sanger Sequencing ◽  
Pancreatic Cyst ◽  
Cyst Fluid ◽  
Pancreatic Cysts ◽  
Next Generation ◽  
Advanced Neoplasia ◽  
Generation Sequencing ◽  
Pancreatic Cyst Fluid

ObjectiveDNA-based testing of pancreatic cyst fluid (PCF) is a useful adjunct to the evaluation of pancreatic cysts (PCs). Mutations in KRAS/GNAS are highly specific for intraductal papillary mucinous neoplasms (IPMNs) and mucinous cystic neoplasms (MCNs), while TP53/PIK3CA/PTEN alterations are associated with advanced neoplasia. A prospective study was performed to evaluate preoperative PCF DNA testing.DesignOver 43-months, 626 PCF specimens from 595 patients were obtained by endoscopic ultrasound (EUS)-fine needle aspiration and assessed by targeted next-generation sequencing (NGS). Molecular results were correlated with EUS findings, ancillary studies and follow-up. A separate cohort of 159 PCF specimens was also evaluated for KRAS/GNAS mutations by Sanger sequencing.ResultsKRAS/GNAS mutations were identified in 308 (49%) PCs, while alterations in TP53/PIK3CA/PTEN were present in 35 (6%) cases. Based on 102 (17%) patients with surgical follow-up, KRAS/GNAS mutations were detected in 56 (100%) IPMNs and 3 (30%) MCNs, and associated with 89% sensitivity and 100% specificity for a mucinous PC. In comparison, KRAS/GNAS mutations by Sanger sequencing had a 65% sensitivity and 100% specificity. By NGS, the combination of KRAS/GNAS mutations and alterations in TP53/PIK3CA/PTEN had an 89% sensitivity and 100% specificity for advanced neoplasia. Ductal dilatation, a mural nodule and malignant cytopathology had lower sensitivities (42%, 32% and 32%, respectively) and specificities (74%, 94% and 98%, respectively).ConclusionsIn contrast to Sanger sequencing, preoperative NGS of PCF for KRAS/GNAS mutations is highly sensitive for IPMNs and specific for mucinous PCs. In addition, the combination of TP53/PIK3CA/PTEN alterations is a useful preoperative marker for advanced neoplasia.

Sign in / Sign up

Export Citation Format

Share Document